Reading JUNS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JUNS free→Reading JUNS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JUNS free→QuarterlyIQ Insights · JUNS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing describes compensatory arrangements and equity grants, not a management change.
Entry into a Material Definitive Agreement On May 20, 2026, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 7,142,858 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Co…
Other Events. On May 19, 2026, the Company and PharmAla executed the Term Sheet describing a potential licensing transaction pursuant to which the Company would acquire from PharmAla exclusive and perpetual U.S. rights to ALA-002, a proprietary, next-generation MDMA formulation, together with related intellectual property, regulatory materials, tangible inventory, and certain contractual and regulatory rights (collectively, the “ Assets ”), subject to the Company’s compliance with the definit…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bi…
As disclosed in the Signing 8-K, on October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (as amended on November 19, 2025, the “SEPA”) and a related Registration Rights Agreement with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”). In connection with the SEPA, Yorkville agreed to advance to the Company up to $6.0 million which was paid in two tranches in exchange for the Company’s issuance to Yorkville of convertible promissory notes (each,…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Unregistered Sales of Equity Securities. The information set forth in
As disclosed in the Signing 8-K, on October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) and a related Registration Rights Agreement. On December 11, 2025, the Company satisfied the condition set forth in the SEPA for the Company to have a registration statement under the Securities Act of 1933, as amended (the “Securities Act”) declared effective by the SEC, registering for resale the shares of our common stock, par value $0.0001 per share (“Common Stoc…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As further described under
Entry Into a Material Definitive Agreement. On October 24, 2025, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into a Standby Equity Purchase Agreement (as amended from time to time, the “SEPA”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of October 24, 2025, with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”), pursuant to which the Company has the right to sell to Yorkville up to $20…
Unregistered Sales of Equity Securities. The information set forth in
Entry Into a Material Definitive Agreement. Standby Equity Purchase Agreement On October 24, 2025, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into a Standby Equity Purchase Agreement (the “SEPA”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of October 24, 2025, with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”), pursuant to which the Company has the right to sell to Yorkville up to…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Approval of Bonus Package to Executive Officers On July 2, 2025, the Compensation Committee of the board of directors (the “Compensation Committee”) of Jupiter Neurosciences, Inc. (the “Company”), after review of the Company’s Final 2025 Budget, approved a bonus package to compensate certain officers of the Company for their role in the success of t…
Changes in Registrant’s Certifying Accountant. Assurance Dimensions, LLC (“AD”), the independent registered public accounting firm for Jupiter Neurosciences, Inc. advised the Company that it was resigning as the independent registered accounting for the Company, effective as of April 16, 2025, as a result of its decision to discontinue its PCAOB registrants practice. Concurrent with such resignation, the Audit Committee of the Board of Directors of the Company approved the engagement of Cherr…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On March 21, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ. Listing Rule 5550(a)(2) requires the registrant to maint…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.